nach oben

Annals of Hematology

Erschienen in:

04.09.2023 | Review Article

Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives

verfasst von: Ivan Krecak, Srdan Verstovsek, Marko Lucijanic

Erschienen in: Annals of Hematology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

The exact prognostic role of cardiovascular (CV) risk factors in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often masked by other MPN-related features that bear strong prognostic impact on thrombotic risk. Therefore, current MPN treatment is not primarily guided by presence of CV risk factors. Treatment of CV risk factors in MPN patients usually mirrors that from the general population, despite the fact that CV risk factors in MPNs have their own specificities. Moreover, the optimal target levels for different metabolic deflections in MPNs (i.e., low-density lipoprotein, serum uric acid, or glycated hemoglobin levels) have not been defined. In the current review, we separately discuss the most important aspects of every individual CV risk factor (arterial hypertension, hyperlipidemia, chronic kidney disease, smoking, diabetes mellitus, hyperuricemia, and obesity and cachexia) in MPNs, summarize recent advances in the field, and propose future directions and research areas which may be needed to appropriately manage CV risk factors in MPNs.

Krecak I, Lucijanic M, Verstovsek S (2022) Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep 17(5):155–169. https://doi.org/10.1007/s11899-022-00670-8CrossRefPubMed

Hasselbalch HC, Bjørn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm 2015:102476. https://doi.org/10.1155/2015/102476CrossRefPubMedPubMedCentral

Holik H, Krečak I, Lucijanić M, Samardžić I, Pilipac D, Vučinić Ljubičić I, Coha B, Kitter Pipić A, Miškić B, Zupančić-Šalek S (2023) Hip and knee osteoarthritis in patients with chronic myeloproliferative neoplasms: a cross-sectional study. Life (Basel) 13(6). https://doi.org/10.3390/life13061388

Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Aralica G, Gecek I, Pejsa V, Kusec R (2017) Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. Leuk Lymphoma 58(10):2497–2500. https://doi.org/10.1080/10428194.2017.1296146CrossRefPubMed

Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317–325. https://doi.org/10.7326/m17-0028CrossRefPubMedPubMedCentral

Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. https://doi.org/10.1002/ajh.27002

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369. https://doi.org/10.1038/bcj.2015.94CrossRefPubMedPubMedCentral

Krecak I, Skelin M, Verstovsek S (2023) Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Rev Hematol 16(5):305–316. https://doi.org/10.1080/17474086.2023.2199151CrossRefPubMed

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133. https://doi.org/10.1182/blood-2012-07-444067CrossRefPubMed

10.

Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T (2020) Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J 10(2):21. https://doi.org/10.1038/s41408-020-0289-2CrossRefPubMedPubMedCentral

11.

Krečak I, Morić Perić M, Zekanović I, Holik H, Coha B, Gverić-Krečak V, Lucijanić M (2021) No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera. Oncol Res Treat 44(4):201–203. https://doi.org/10.1159/000514347CrossRefPubMed

12.

Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F, Perez A, Bono M, Russo A, Siragusa S (2020) Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat 43(10):526–530. https://doi.org/10.1159/000509376CrossRefPubMed

13.

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7(12):662. https://doi.org/10.1038/s41408-017-0035-6CrossRefPubMedPubMedCentral

14.

Sørensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, Hasselbalch HC (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 193(1):83–92. https://doi.org/10.1111/bjh.17130CrossRefPubMed

15.

Krečak I, Holik H, Coha B, Perić MM, Zekanović I, Krečak MV, Gverić-Krečak V, Lucijanić M (2021) Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera. Ann Hematol 100(5):1335–1336. https://doi.org/10.1007/s00277-021-04431-0CrossRefPubMed

16.

Lekovic D, Gotic M, Sefer D, Mitrovic-Ajtic O, Cokic V, Milic N (2015) Predictors of survival and cause of death in patients with essential thrombocythemia. Eur J Haematol 95(5):461–466. https://doi.org/10.1111/ejh.12517CrossRefPubMed

17.

Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N (2023) Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis 55(2):263–272. https://doi.org/10.1007/s11239-022-02751-0CrossRefPubMed

18.

Lekovic D, Gotic M, Milic N, Miljic P, Mitrovic M, Cokic V, Elezovic I (2014) The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Med Oncol 31(10):231. https://doi.org/10.1007/s12032-014-0231-1CrossRefPubMed

19.

Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B (2019) Influence of blood count, cardiovascular risks, inherited thrombophilia, and JAK2 V617F burden allele on type of thrombosis in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 19(1):53–63. https://doi.org/10.1016/j.clml.2018.08.020CrossRefPubMed

20.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021–3023. https://doi.org/10.1182/blood-2014-07-591610CrossRefPubMed

21.

Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H (2014) Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol 93(2):103–111. https://doi.org/10.1111/ejh.12307CrossRefPubMed

22.

Rusak T, Misztal T, Piszcz J, Tomasiak M (2014) Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients. Free Radic Res 48(2):230–238. https://doi.org/10.3109/10715762.2013.860225CrossRefPubMed

23.

Zidek W, Tenschert W, Karoff C, Vetter H (1985) Treatment of resistant hypertension by phlebotomy. Klin Wochenschr 63(16):762–764. https://doi.org/10.1007/bf01733828CrossRefPubMed

24.

Xiong XJ, Wang PQ, Li SJ (2019) Blood-letting therapy for hypertension: a systematic review and meta-analysis of randomized controlled trials. Chin J Integr Med 25(2):139–146. https://doi.org/10.1007/s11655-018-3009-2CrossRefPubMed

25.

Satou R, Penrose H, Navar LG (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep 20(12):100. https://doi.org/10.1007/s11906-018-0900-0CrossRefPubMedPubMedCentral

26.

Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, Borghi C, Piani F, Cara-Fuentes G, Bjornstad P, Lanaspa MA, Johnson RJ (2020) Uric acid and hypertension: an update with recommendations. Am J Hypertens 33(7):583–594. https://doi.org/10.1093/ajh/hpaa044CrossRefPubMedPubMedCentral

27.

Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, Marathias KP (1999) Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 106(2):158–164. https://doi.org/10.1016/s0002-9343(98)00390-8CrossRefPubMed

28.

Vrsalovic MM, Pejsa V, Veic TS, Kolonic SO, Ajdukovic R, Haris V, Jaksic O, Kusec R (2007) Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status. Cancer Biol Ther 6(9):1434–1436. https://doi.org/10.4161/cbt.6.9.4568CrossRefPubMed

29.

Barbui T, Masciulli A, Ghirardi A, Carobbio A (2017) ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood 129(9):1226–1227. https://doi.org/10.1182/blood-2016-11-752600CrossRefPubMed

30.

Krečak I, Morić Perić M, Zekanović I, Holik H, Coha B, Gverić-Krečak V, Lucijanić M (2021) Beneficial effect of ACE inhibitors on kidney function in polycythemia vera. Wien Klin Wochenschr 133(15-16):808–815. https://doi.org/10.1007/s00508-021-01812-3CrossRefPubMed

31.

Lucijanic M, Veic P, Aric I, Tupek KM, Soric E, Sabljic A, Vlasac Glasnovic J, Stoos-Veic T, Krecak I, Kusec R (2023) Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time. Ann Hematol 102(7):1955–1956. https://doi.org/10.1007/s00277-023-05305-3CrossRefPubMed

32.

Mulas O, Mola B, Costa A, Pittau F, Mantovani D, Dessì S, Fronteddu A, La Nasa G, Caocci G (2023) Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension. Ann Hematol. https://doi.org/10.1007/s00277-023-05417-w

33.

Akdi A, Özeke Ö, Karanfil M, Ertem AG, Yayla Ç, Demirtaş K, Güney T, Ünal S, Selçuk MT (2020) Diurnal rhythm of blood pressure in patients with polycythemia vera. Blood Press Monit 25(2):69–74. https://doi.org/10.1097/mbp.0000000000000427CrossRefPubMed

34.

Jóźwik-Plebanek K, Dobrowolski P, Lewandowski J, Narkiewicz K, Sikorska A, Siński M, Eisenhofer G, Schmieder RE, Januszewicz M, Windyga J, Prejbisz A, Januszewicz A (2020) Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia vera. Pol Arch Intern Med 130(7-8):607–614. https://doi.org/10.20452/pamw.15473CrossRefPubMed

35.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455CrossRefPubMed

36.

Fujita H, Hamaki T, Handa N, Ohwada A, Tomiyama J, Nishimura S (2012) Hypocholesterolemia in patients with polycythemia vera. J Clin Exp Hematop 52(2):85–89. https://doi.org/10.3960/jslrt.52.85CrossRefPubMed

37.

Krečak I, Holik H, Morić-Perić M, Zekanović I, Coha B, Gverić-Krečak V (2020) The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol 99(4):911–912. https://doi.org/10.1007/s00277-020-03950-6CrossRefPubMed

38.

Podoltsev N, Zhu M, Wang R, Zeidan AM, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X (2018) Use of statins, survival and incidence of thrombosis among older adults with polycythemia vera: a population-based study. Blood 132(Supplement 1):3580–3580. https://doi.org/10.1182/blood-2018-99-119272CrossRef

39.

Kristensen DT, Øvlisen AK, Jakobsen LH, Severinsen MT, Hannig LH, Starklint J, Hilsøe MH, Vallentin AP, Brabrand M, Hasselbalch HC, El-Galaly TC, Roug AS (2023) Use of statins and risk of myeloproliferative neoplasms — a Danish nationwide case-control study. Blood Adv. https://doi.org/10.1182/bloodadvances.2023009784

40.

Lucijanic M, Galusic D, Krecak I, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Kusec R (2020) Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Ann Hematol 99(12):2779–2785. https://doi.org/10.1007/s00277-020-04239-4CrossRefPubMed

41.

Krečak I, Holik H, Martina MP, Zekanović I, Coha B, Gverić-Krečak V (2020) Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol 112(3):377–384. https://doi.org/10.1007/s12185-020-02898-7CrossRefPubMed

42.

Christensen AS, Møller JB, Hasselbalch HC (2014) Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 38(4):490–495. https://doi.org/10.1016/j.leukres.2014.01.014CrossRefPubMed

43.

Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N (2019) Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 104(11):e506–e509. https://doi.org/10.3324/haematol.2018.208876CrossRefPubMedPubMedCentral

44.

Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M et al (2021) Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN Bioregistry. Cancers (Basel) 13(16). https://doi.org/10.3390/cancers13164086

45.

Krečak I, Holik H, Morić Perić M, Zekanović I, Coha B, Lucijanić M (2022) Chronic kidney disease has a higher prevalence in polycythemia vera than in secondary polycythemia, a matched case–control analysis. Indian J Hematol Blood Transfus. https://doi.org/10.1007/s12288-022-01624-z

46.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PloS One 11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765CrossRefPubMedPubMedCentral

47.

Krečak I, Holik H, Lucijanić M (2022) The prevalence of simple kidney cysts in polycythemia vera and its clinical associations. Indian J Hematol Blood Transfus 38(2):429–431. https://doi.org/10.1007/s12288-021-01515-9CrossRefPubMedPubMedCentral

48.

Lucijanic M, Krecak I, Kusec R (2022) Renal disease associated with chronic myeloproliferative neoplasms. Expert Rev Hematol 15(2):93–96. https://doi.org/10.1080/17474086.2022.2039117CrossRefPubMed

49.

Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D’Agati VD, Nasr SH (2011) Myeloproliferative neoplasms cause glomerulopathy. Kidney Int 80(7):753–759. https://doi.org/10.1038/ki.2011.147CrossRefPubMed

50.

Alexander MP, Nasr SH, Kurtin PJ, Casey ET, Hernandez LP, Fidler ME, Sethi S, Cornell LD (2015) Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Mod Pathol 28(12):1574–1583. https://doi.org/10.1038/modpathol.2015.117CrossRefPubMed

51.

Büttner-Herold M, Sticht C, Wiech T, Porubsky S (2021) Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms. Histopathology 78(5):738–748. https://doi.org/10.1111/his.14282CrossRefPubMed

52.

Person F, Meyer SC, Hopfer H, Menter T (2021) Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Virchows Arch 479(5):1013–1020. https://doi.org/10.1007/s00428-021-03129-yCrossRefPubMedPubMedCentral

53.

Holik H, Lucijanic M, Krecak I (2023) Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease. Ann Hematol 102(7):1963–1965. https://doi.org/10.1007/s00277-023-05296-1CrossRefPubMed

54.

Larsen MK, Skov V, Kjaer L, Møller-Palacino NA, Pedersen RK, Andersen M, Ottesen JT, Cordua S, Poulsen HE, Dahl M, Knudsen TA, Eickhardt-Dalbøge CS, Koschmieder S, Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG, Stiehl T, Hasselbalch HC, Ellervik C (2022) Clonal haematopoiesis of indeterminate potential and impaired kidney function—a Danish general population study with 11 years follow-up. Eur J Haematol 109(5):576–585. https://doi.org/10.1111/ejh.13845CrossRefPubMedPubMedCentral

55.

Vlasschaert C, McNaughton AJM, Chong M, Cook EK, Hopman W, Kestenbaum B, Robinson-Cohen C, Garland J, Moran SM, Paré G, Clase CM, Tang M, Levin A, Holden R, Rauh MJ, Lanktree MB (2022) Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J Am Soc Nephrol 33(5):985–995. https://doi.org/10.1681/asn.2021060774CrossRefPubMedPubMedCentral

56.

Dawoud AAZ, Gilbert RD, Tapper WJ, Cross NCP (2022) Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 36(2):507–515. https://doi.org/10.1038/s41375-021-01382-3CrossRefPubMed

57.

Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657. https://doi.org/10.1002/rth2.12657CrossRefPubMedPubMedCentral

58.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. https://doi.org/10.1056/NEJMoa1208500CrossRefPubMed

59.

Trivedi PM, Graham KL, Scott NA, Jenkins MR, Majaw S, Sutherland RM, Fynch S, Lew AM, Burns CJ, Krishnamurthy B, Brodnicki TC, Mannering SI, Kay TW, Thomas HE (2017) Repurposed JAK1/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes 66(6):1650–1660. https://doi.org/10.2337/db16-1250CrossRefPubMed

60.

Botana M, Escalada J, Merchante Á, Reyes R, Rozas P (2022) Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther 13(Suppl 1):5–17. https://doi.org/10.1007/s13300-022-01277-1CrossRefPubMedPubMedCentral

61.

Gangat N, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: impact on hemoglobin/hematocrit levels and outcomes among 11 consecutive patients. Am J Hematol. https://doi.org/10.1002/ajh.27048

62.

Gangat N, Alkhateeb H, Reichard K, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: a Mayo Clinic series of nine consecutive cases. Am J Hematol. https://doi.org/10.1002/ajh.27034

63.

Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, Begna KH, Pardanani A, Tefferi A (2023) Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol 98(7):E165–e167. https://doi.org/10.1002/ajh.26933CrossRefPubMed

64.

Krečak I, Zekanović I, Holik H, Morić Perić M, Coha B, Gverić-Krečak V (2022) Estimating plasma volume using the Strauss-derived formula may improve prognostication in polycythemia vera. Int J Lab Hematol 44(2):e69–e71. https://doi.org/10.1111/ijlh.13716CrossRefPubMed

65.

Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, Perisa V, Peric MM, Zekanovic I, Kusec R (2023) Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. Biochem Med (Zagreb) 33(2):020901. https://doi.org/10.11613/bm.2023.020901CrossRefPubMed

66.

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154(8):554–559. https://doi.org/10.7326/0003-4819-154-8-201104190-00007CrossRefPubMed

67.

Ren Q, Lv X, Yang L, Yue J, Luo Y, Zhou L, Meng S, Yang S, Puchi B, Zhou X, Ji L (2020) Erythrocytosis and performance of HbA1c in detecting diabetes on an oxygen-deficient plateau: a population-based study. J Clin Endocrinol Metab 105(4). https://doi.org/10.1210/clinem/dgaa001

68.

Karsegard J, Wicky J, Mensi N, Caulfield A, Philippe J (1997) Spurious glycohemoglobin values associated with hydroxyurea treatment. Diabetes Care 20(7):1211–1212. https://doi.org/10.2337/diacare.20.7.1211CrossRefPubMed

69.

Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL (2021) Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer 21(1):691. https://doi.org/10.1186/s12885-021-08439-7CrossRefPubMedPubMedCentral

70.

Lindholm Sørensen A, Hasselbalch HC (2016) Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol 97(1):63–69. https://doi.org/10.1111/ejh.12684CrossRefPubMed

71.

Duncombe AS, Anderson LA, James G, de Vocht F, Fritschi L, Mesa R, Clarke M, McMullin MF (2020) Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Hemasphere 4(1):e327. https://doi.org/10.1097/hs9.0000000000000327CrossRefPubMedPubMedCentral

72.

Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1–11. https://doi.org/10.1016/j.ejim.2020.07.006CrossRefPubMed

73.

Gonzalez-Martin G, Cano J, Carriazo S, Kanbay M, Perez-Gomez MV, Fernandez-Prado R, Ortiz A (2020) The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality. Clin Kidney J 13(6):936–947. https://doi.org/10.1093/ckj/sfaa236CrossRefPubMedPubMedCentral

74.

Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM (2022) Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10359):1195–1205. https://doi.org/10.1016/s0140-6736(22)01657-9CrossRefPubMed

75.

Yu T, Weinreb N, Wittman R, Wasserman LR (1976) Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum 5(3):247–256. https://doi.org/10.1016/0049-0172(76)90026-3CrossRefPubMed

76.

Krecak I, Lucijanic M, Gveric-Krecak V, Durakovic N (2020) Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. Leuk Lymphoma. https://doi.org/10.1080/10428194.2020.1731503

77.

Lucijanic M, Krecak I, Galusic D, Sedinic M, Holik H, Perisa V, Moric Peric M, Zekanovic I, Stoos-Veic T, Pejsa V, Kusec R (2022) Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis. Wien Klin Wochenschr 134(3-4):97–103. https://doi.org/10.1007/s00508-020-01802-xCrossRefPubMed

78.

Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ (2019) Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 15:89–100. https://doi.org/10.2147/vhrm.S168946CrossRefPubMedPubMedCentral

79.

Christensen SF, Scherber RM, Brochmann N, Goros M, Gelfond J, Andersen CL, Flachs EM, Mesa R (2020) Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association. Cancers (Basel) 12(8). https://doi.org/10.3390/cancers12082202

80.

Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D’Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L et al (2021) Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematol Oncol 39(3):409–418. https://doi.org/10.1002/hon.2843CrossRefPubMed

81.

Leiba A, Duek A, Afek A, Derazne E, Leiba M (2017) Obesity and related risk of myeloproliferative neoplasms among israeli adolescents. Obesity (Silver Spring) 25(7):1187–1190. https://doi.org/10.1002/oby.21863CrossRefPubMed

82.

Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK (2023) Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel) 15(2). https://doi.org/10.3390/cancers15020485

83.

BHL H, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM (2022) Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Rev 41(3):491–515. https://doi.org/10.1007/s10555-022-10046-2CrossRef

84.

Liu XZ, Pedersen L, Halberg N (2021) Cellular mechanisms linking cancers to obesity. Cell Stress 5(5):55–72. https://doi.org/10.15698/cst2021.05.248CrossRefPubMedPubMedCentral

85.

Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R (2018) Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126–133. https://doi.org/10.1007/s00508-018-1318-zCrossRefPubMed

86.

Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD (2018) Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Adv 2(15):1980–1984. https://doi.org/10.1182/bloodadvances.2018018051CrossRefPubMedPubMedCentral

87.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D’Adda M, Crugnola M, Bosi C, Heidel F, Molica M et al (2019) Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Ann Hematol 98(4):889–896. https://doi.org/10.1007/s00277-018-3569-1CrossRefPubMed

88.

Lucijanic M, Galusic D, Soric E, Sedinic M, Cubela M, Huzjan Korunic R, Pejsa V, Kusec R (2021) Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol 100(4):1105–1106. https://doi.org/10.1007/s00277-020-04243-8CrossRefPubMed

89.

Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM (2020) Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood 135(13):1062–1066. https://doi.org/10.1182/blood.2019003050CrossRefPubMed

90.

Leiva O, Jenkins A, Rosovsky RP, Leaf RK, Goodarzi K, Hobbs G (2023) Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation. J Cardiol 81(3):260–267. https://doi.org/10.1016/j.jjcc.2022.10.007CrossRefPubMed

91.

Krečak I, Pivac L, Lucijanić M, Skelin M (2023) Polypharmacy, potentially inappropriate medications, and drug-to-drug interactions in patients with chronic myeloproliferative neoplasms. Biomedicines 11(5). https://doi.org/10.3390/biomedicines11051301

92.

Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M (1925) Kiladjian J-J (2023) Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project. Biomedicines 11(7)

Titel: Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
verfasst von: Ivan Krecak
Srdan Verstovsek
Marko Lucijanic
Publikationsdatum: 04.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 5/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05426-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials

Palliative care for patients with hematologic malignancies in Germany: a nationwide survey on everyday practice and influencing factors from the perspective of treating physicians

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience

The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms

Posttransplant cyclophosphamide beyond haploidentical transplantation